Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Stegeman, Hanneke ^a   Kaanders, Johannes H A M ^a   Verheijen, Marieke M G ^a   Peeters, Wenny J M ^a   Wheeler, Deric L ^b   Iida, Mari ^b   Grénman, Reidar ^c   van der Kogel, Albert J ^a,b   Span, Paul N ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Head and neck cancer; Kinase inhibitors; Radiation resistance; STAT5; STAT6

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; STAT5A PROTEIN; STAT6 PROTEIN;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY;

ANTINEOPLASTIC AGENTS; BUTADIENES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; ISOXAZOLES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; NITRILES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RADIATION TOLERANCE; STAT5 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; THIAZOLES; TUMOR SUPPRESSOR PROTEINS;

EID: 84887086849     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-133     Document Type: Article

References (33)

1. Harari PM, Ritter MA, Petereit DG, Mehta MP. Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Curr Probl Cancer 2004, 28:7-40. 10.1016/j.currproblcancer.2003.10.002, 14688789.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
3. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956. 10.1038/onc.2008.19, 2903615, 18297114.
4. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486. 10.1016/j.ccr.2011.09.003, 22014573.
5. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011, 17:4425-4438. 10.1158/1078-0432.CCR-10-3339, 3138116, 21622718.
6. Stegeman H, Kaanders JH, van der Kogel AJ, Iida M, Wheeler DL, Span PN, Bussink J. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol 2013, 106:383-389. 10.1016/j.radonc.2013.02.001, 23453541.
7. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008, 105:692-697. 10.1073/pnas.0707270105, 2206598, 18180459.
8. Affolter A, Fruth K, Brochhausen C, Schmidtmann I, Mann WJ, Brieger J. Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism. Head Neck 2011, 33:1448-1457. 10.1002/hed.21623, 21928417.
9. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9:288-296. 10.1016/S1470-2045(08)70073-1, 18308254.
10. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009, 92:316-322. 10.1016/j.radonc.2009.06.031, 2754282, 19615770.
11. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012, 105:241-249. 10.1016/j.radonc.2012.08.010, 23010482.
12. Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grenman R, Span PN, Bussink J. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer 2012, 12:463. 10.1186/1471-2407-12-463, 3517352, 23046567.
13. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105. 10.1042/0264-6021:3510095, 1221339, 10998351.
14. Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O. Molecular interplay between leptin, insulin-like growth factor-1, and beta-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener 2011, 6:41. 10.1186/1750-1326-6-41, 3121598, 21651786.
15. Moynihan B, Tolloczko B, Michoud MC, Tamaoka M, Ferraro P, Martin JG. MAP kinases mediate interleukin-13 effects on calcium signaling in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2008, 295:L171-L177. 10.1152/ajplung.00457.2007, 2494781, 18441092.
16. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344. 10.1128/MMBR.68.2.320-344.2004, 419926, 15187187.
17. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, Dittmann K, Baumann M, Dikomey E, Rodemann HP. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 2006, 12:4119-4126. 10.1158/1078-0432.CCR-05-2454, 16818713.
18. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int J Radiat Oncol Biol Phys 2012, 83:e43-e52. 10.1016/j.ijrobp.2011.11.037, 22516386.
19. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010, 7:493-507. 10.1038/nrclinonc.2010.97, 2929287, 20551942.
20. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71. 10.1016/j.ccr.2010.10.031, 3025058, 21215704.
21. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012, 72:3228-3237. 10.1158/0008-5472.CAN-11-3747, 3515079, 22552284.
22. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22:337-358. 10.1023/A:1023772912750, 12884910.
23. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004, 4:470-480. 10.1038/nrc1366, 15170449.
24. Kim MJ, Byun JY, Yun CH, Park IC, Lee KH, Lee SJ. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation. Mol Cancer Res 2008, 6:1872-1880. 10.1158/1541-7786.MCR-08-0084, 19074832.
25. Bonner JA, Vroman BT, Christianson TJ, Karnitz LM. Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells. Int J Radiat Oncol Biol Phys 1998, 42:921-925. 10.1016/S0360-3016(98)00325-3, 9845123.
26. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 2010, 13:67-78. 10.1016/j.drup.2010.04.001, 20471303.
27. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 2008, 14:7682-7690. 10.1158/1078-0432.CCR-08-1328, 3422894, 19047094.
28. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol 2009, 92:339-344. 10.1016/j.radonc.2009.06.022, 19616333.
29. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, van Herpen CM, Kaanders JH, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011, 121:3100-3108. 10.1172/JCI43656, 3148725, 21765211.
30. Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007, 83:238-248. 10.1016/j.radonc.2007.04.006, 17502118.
31. Stegeman H, Span PN, Rijken PF, Cockx SC, Wheeler DL, Iida M, van der Kogel AJ, Kaanders JH, Bussink J. Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. Transl Oncol 2013, 6:413-419. 3730016, 23908684.
32. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011, 117:2112-2119. 10.1002/cncr.25769, 3117018, 21523723.
33. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695. 10.1200/JCO.2011.35.5263, 22025163.